AKBA vs DVA
AKBA: A biopharmaceutical company specialized in kidney disease therapeutics with a commercial portfolio for anemia and mineral metabolism and a pipeline of rare disease assets. DVA: Leading US dialysis and integrated kidney care provider serving end-stage renal disease patients across clinical centers, home-based settings, and transplant support globally.
Side-by-side fundamentals
| Metric | AKBA | DVA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.26 | $232.08 | |
| Market cap as of 2026-07-23 | $349M | $15.0B | |
| P/E as of 2026-07-23 | n/a | 19.22 | |
| PEG as of 2026-07-23 | n/a | 7.29 | |
| Net margin as of 2026-07-23 | -8.8% | +5.7% | DVA higher |
| Gross margin as of 2026-07-23 | +79.3% | +32.5% | AKBA higher |
| Operating margin as of 2026-07-23 | +2.3% | +15.0% | DVA higher |
| ROE as of 2026-07-23 | -62.7% | +181.2% | DVA higher |
| ROA as of 2026-07-23 | -5.7% | +4.5% | DVA higher |
| Debt / equity as of 2026-07-23 | 7.09 | 77.99 | AKBA lower |
| Revenue growth (YoY) as of 2026-07-23 | +25.7% | +6.7% | AKBA higher |
| Revenue CAGR (3y) SEC XBRL | -6.9% | +5.5% | DVA higher |
| Beta as of 2026-07-23 | 0.26 | 0.88 | |
| 1-year return as of 2026-07-22 close | -67.3% | +58.9% | DVA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.